The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Oil steadies as COVID-19-induced demand worries persist

Thu, 28th Jan 2021 05:31

* Delays with coronavirus vaccines in EU fuels demand
concerns

* China limits Lunar New Year trips as COVID cases rise

* Dollar gains on safe-haven bids, pressuring oil prices
(Updates prices)

By Ahmad Ghaddar

LONDON, Jan 28 (Reuters) - Oil steadied on Thursday after
early declines fuelled by delays to vaccine rollouts and fresh
travel curbs to prevent new coronavirus outbreaks.

Brent crude futures were up 8 cents, or 0.1%, at
$55.89 a barrel by 1331 GMT, having hit a session low of $55.31.

U.S. West Texas Intermediate (WTI) crude futures were
down 8 cents, or 0.2%, at $52.77 after dropping as low as
$52.22.

Oil prices were supported by data on Wednesday showing a
huge 10 million barrel decline in U.S. crude inventories last
week, which analysts said was because of a pick-up in U.S. crude
exports and a drop in imports.

But attention is returning to demand as contagious variants
drive a rise in coronavirus infections and a slower rollout of
vaccines in Europe and travel curbs in China are expected to
limit fuel consumption.

"Any sort of demand-related optimism remains on pause amid
the continued rise of new COVID-19 cases across key demand
centres and restricted mobility and public activity,"
consultants JBC Energy said.

Stricter vaccine checks by the European Union and delivery
hold-ups from AstraZeneca and Pfizer have slowed
the rollout of shots.

Adding to the bearishness over demand, China, the world's
second-largest oil consumer, faces a surge in coronavirus cases
and is seeking to limit travel as it heads into what is normally
the busiest travel season of the year, the Lunar New Year
holiday.

The Chinese Ministry of Transport has forecast the number of
trips that will be taken will rise 15% from last year, when the
virus was raging, but is still likely to be down 40% from 2019.

A strengthening dollar also weighed on prices. Buyers
using other currencies must pay more for dollar-denominated oil
when the greenback rises.

Data out later on Thursday is expected to show the economy
of the United States, the world's biggest oil user, contracted
in 2020 at its sharpest pace since 1946 because of the
pandemic.
(Additional reporting by Shu Zhang in Singapore and Sonali Paul
in Melbourne
Editing by Barbara Lewis and David Goodman
)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.